Provided by Tiger Fintech (Singapore) Pte. Ltd.

Intellia Therapeutics

6.63
-0.2600-3.77%
Post-market: 6.59-0.0400-0.60%19:42 EDT
Volume:4.81M
Turnover:31.92M
Market Cap:686.32M
PE:-1.26
High:6.91
Open:6.83
Low:6.43
Close:6.89
Loading ...

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
04 Apr

Intellia Therapeutics announces first patient dosed in MAGNITUDE-2 trial

TIPRANKS
·
03 Apr

BRIEF-Intellia Therapeutics Announces First Patient Dosed In The Magnitude-2 Phase 3 Study Of Nexiguran Ziclumeran (Nex-Z), Treatment For Transthyretin (Attr) Amyloidosis With Polyneuropathy

Reuters
·
03 Apr

Intellia Therapeutics Inc: Plans to Submit a Biologics Licensing Application for Attrv-Pn by 2028

THOMSON REUTERS
·
03 Apr

Intellia Therapeutics Announces First Patient Dosed in the Magnitude-2 Phase 3 Study of Nexiguran Ziclumeran (Nex-Z), a One-Time Gene Editing-Based Treatment for Transthyretin (Attr) Amyloidosis With Polyneuropathy

THOMSON REUTERS
·
03 Apr

Intellia Therapeutics Announces First Patient Dosed in the MAGNITUDE-2 Phase 3 Study of Nexiguran Ziclumeran (nex-z), a One-Time Gene Editing-Based Treatment for Transthyretin (ATTR) Amyloidosis with Polyneuropathy

GlobeNewswire
·
03 Apr

RBC Cuts Price Target on Intellia Therapeutics to $32 From $37, Keeps Outperform, Speculative Risk

MT Newswires Live
·
03 Apr

Is Intellia Therapeutics, Inc. (NTLA) the Best Gene-Editing Stock to Buy?

Insider Monkey
·
02 Apr

Biotech stocks slide as Marks resignation seen being negative for sector

TipRanks
·
01 Apr

Intellia Focuses on Pipeline Development Amid Stiff Competition

Zacks
·
31 Mar

Promising Genomics & Synthetic Biology Stocks to Consider in 2025

Zacks
·
28 Mar

Analysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NTLA) and Wave Life Sciences (WVE)

TIPRANKS
·
26 Mar

Intellia Therapeutics' Gene-Editing Drug Gets FDA Designation

MT Newswires Live
·
26 Mar

BRIEF-Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (nex-z)

Reuters
·
26 Mar

Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (Rmat) Designation Granted to Nexiguran Ziclumeran (Nex-Z) for the Treatment of Transthyretin (Attr) Amyloidosis With Cardiomyopathy

THOMSON REUTERS
·
26 Mar

Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (nex-z) for the Treatment of Transthyretin (ATTR) Amyloidosis with Cardiomyopathy

GlobeNewswire
·
26 Mar

CRISPR Therapeutics Stock Trades Near 52-Week Low: Time to Buy or Sell?

Zacks
·
19 Mar

BUZZ-H.C. Wainwright starts coverage on Intellia with 'buy' rating on optimism for heart disease therapies

Reuters
·
06 Mar

HC Wainwright Initiates Intellia Therapeutics at Buy With $30 Price Target

MT Newswires Live
·
05 Mar

Intellia Therapeutics initiated with a Buy at H.C. Wainwright

TIPRANKS
·
05 Mar